Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-5074 in severe chronic kidney disease
NCT02837237Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Jul 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ocederenone in chronic kidney disease (CKD), sponsored by KBP Biosciences. Primary endpoint: Number of Participants With Treatment-related Adverse Events at 312 hours. Started Jul 2016; status: completed.
02
Drugs
ocederenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02837237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837237.